Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses. Not affiliated with any government agency. Always verify information with official sources.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Not a government website.

Home
/
Brands
/
Imprimis NJOF, LLC

Imprimis NJOF, LLC Recalls

All product recalls associated with Imprimis NJOF, LLC.

Get alerts for this brand

Recall Summary

Total Recalls

14

Past Year

4

Class I (Serious)

0

Most Recent

Oct 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–14 of 14 recalls

Klarity-C Drops (Imprimis) – Subpotent Medication (2025)

Subpotent Drug

FDAOct 20, 2025Nationwide• Imprimis NJOF, LLC

Tropicamide Ophthalmic Solution (Imprimis NJOF) – Potency Concern (2025)

Sub-Potent Drug: Subpotent assay results during stability testing.

FDAJul 9, 2025Nationwide• Imprimis NJOF, LLC

Epinephrine Lidocaine HCL (Imprimis NJOF) – Sub-Potent Drug (2025)

Sub-Potent Drug: Subpotent assay results during stability testing.

Jul 9, 2025

Nationwide

• Imprimis NJOF, LLC

Tropicamide Ophthalmic Solution (Imprimis) – Sub-Potent Drug (2025)

Sub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-110.0% of the label claim.

FDAFeb 24, 2025FL, NY• Imprimis NJOF, LLC

Dexamethasone-Moxifloxacin Injection (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Prednisolone-Moxifloxacin Suspension (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Moxifloxacin Injection (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Epinephrine-Lidocaine Injection (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Klarity-C Ophthalmic Emulsion (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Epinephrine-Lidocaine Injection (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Dexamethasone-Moxifloxacin Suspension (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Moxifloxacin Injection (Imprimis) – Sterility Issue (2024)

Lack of Assurance of Sterility

FDAMay 14, 2024Nationwide• Imprimis NJOF, LLC

Prednisolone-Moxifloxacin-Bromfenac Solution (Imprimis) – Subpotent Drug (2024)

Subpotent Drug

FDAApr 10, 2024Nationwide• Imprimis NJOF, LLC

Epinephrine-Lidocaine HCl Solution (Imprimis) – Assay Specification (2024)

Out of specification for assay

FDAApr 10, 2024Nationwide• Imprimis NJOF, LLC